High Tech Pharm

106190 · KOSDAQ · ₩106190 · 하이텍팜

₩8,980▲ ₩100 (1.13%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩8,892

vs the current price (₩8,980)

Enterprise value
₩92B
Equity value
₩95B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩5,959
−33.6%
Base
₩8,892
−1.0%
Bull
₩13,909
+54.9%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (13.5%).

Revenue growth

  • -10%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (-12% a year, annual reports), fading to 3% by year 5.

  • -6.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (-12% a year, annual reports), fading to 3% by year 5.

  • -3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (-12% a year, annual reports), fading to 3% by year 5.

  • -0.2%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (-12% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (-12% a year, annual reports), fading to 3% by year 5.

Business

  • 13.5%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3.2%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 4%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 40%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.05, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩69B
Net debt (borrowings and leases − cash and deposits)
−₩2.5B
Shares
10,633,173
Share price
₩8,980
Market cap
₩95B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩77B₩78B₩70B₩62B₩58B₩56B₩56B₩58B
Growth−25.4%1.0%−9.5%−10.0%−6.7%−3.5%−0.2%3.0%
EBIT₩10B₩16B₩13B₩8.4B₩7.9B₩7.6B₩7.6B₩7.8B
EBIT margin13.1%20.1%18.3%13.5%13.5%13.5%13.5%13.5%
After-tax EBIT₩7.3B₩11B₩9.3B₩6.1B₩5.7B₩5.5B₩5.5B₩5.7B
+ Depreciation———₩2B₩1.9B₩1.8B₩1.8B₩1.9B
− Capital spending₩5.1B₩2.1B₩1.9B₩2.5B₩2.3B₩2.2B₩2.2B₩2.3B
− Working capital₩11B₩5.6B−₩73M−₩2.8B−₩1.7B−₩816M−₩45M₩674M
Free cash flow———₩8.4B₩6.9B₩5.9B₩5.1B₩4.5B
Discount factor———0.9310.8670.8080.7520.700
Present value———₩7.8B₩6B₩4.7B₩3.8B₩3.2B

Terminal value ₩95B, worth ₩67B today: 72% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩12,607 a share)Now 0.71×₩9,9400.79×₩12,6891.01×₩17,7651.41×
Price / earnings (last 12 months: ₩1,122 a share)Now 8.01×₩11,49510.2×₩13,62612.1×₩17,45015.6×
P/E on run-rate earnings (Q2 2026 × 4: ₩1,973 a share)Now 4.55×₩20,22010.2×₩23,96912.1×₩30,69715.6×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩9,486₩10,053₩10,747₩11,618₩12,745
6.9%₩8,735₩9,185₩9,725₩10,387₩11,218
7.4%₩8,101₩8,464₩8,892₩9,407₩10,038
7.9%₩7,559₩7,856₩8,201₩8,609₩9,099
8.4%₩7,091₩7,335₩7,617₩7,945₩8,333

Now (TTM)

Market cap
₩95B
Enterprise value
₩93B
P/E
8.0×
P/B
0.7×
P/S
1.4×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩12,020₩14,000₩9,330₩7,271₩9,139
Market cap₩128B₩149B₩99B₩77B₩97B
P/E11.1×10.9×12.3×13.2×—
P/B1.0×1.2×0.9×0.8×1.0×
P/S1.8×1.9×1.3×0.8×1.3×
EV/EBITDA————19.8×
Dividend yield0.0%0.0%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
High Tech Pharm8.0×0.7×1.4×—0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: High Tech Pharm / 하이텍팜 / 106190 / KRX:106190

Source: KRX statistical information